KM
ABBV icon

Kalos Management’s AbbVie ABBV Stock Holding History

Kalos Management’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-165
Closed -$26.3K – 132
2023
Q1 		$26.3K Buy
+165
New +$25.2K 0.05% 128
2022
Q3 		– Sell
-4,325
Closed -$664K – 43
2022
Q2 		$664K Sell
4,325
-652
-13% -$99.6K 0.89% 28
2022
Q1 		$806K Sell
4,977
-12,938
-72% -$1.88M 0.55% 40
2021
Q4 		$2.07M Buy
17,915
+521
+3% +$61.5K 0.56% 38
2021
Q3 		$2.01M Buy
17,394
+14,622
+527% +$1.67M 0.57% 35
2021
Q2 		$315K Sell
2,772
-117
-4% -$13.2K 0.13% 187
2021
Q1 		$327K Sell
2,889
-358
-11% -$38.3K 0.1% 207
2020
Q4 		$344K Buy
3,247
+98
+3% +$9.42K 0.15% 167
2020
Q3 		$297K Buy
3,149
+137
+5% +$12.9K 0.13% 172
2020
Q2 		$288K Buy
+3,012
New +$265K 0.12% 159
2018
Q1 		– Sell
-7,974
Closed -$778K – 128
2017
Q4 		$778K Buy
7,974
+637
+9% +$60K 0.37% 78
2017
Q3 		$652K Buy
7,337
+287
+4% +$21.8K 0.42% 71
2017
Q2 		$511K Sell
7,050
-545
-7% -$36.6K 0.47% 62
2017
Q1 		$495K Buy
7,595
+351
+5% +$22.1K 0.35% 74
2016
Q4 		$454K Sell
7,244
-1,542
-18% -$94.1K 0.37% 72
2016
Q3 		$554K Sell
8,786
-774
-8% -$50.1K 0.47% 67
2016
Q2 		$592K Sell
9,560
-632
-6% -$38.5K 0.46% 74
2016
Q1 		$603K Buy
10,192
+402
+4% +$22.4K 0.5% 65
2015
Q4 		$725K Buy
+9,790
New +$564K 0.54% 61

Other funds holding ABBV

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Kalos Management's ABBV Position: Q2 2023 in Review

Kalos Management sold out of AbbVie (ABBV) in Q2 2023, closing a stake of 165 shares — an estimated $26.3K sold.

Kalos Management first reported a position in ABBV in Q4 2015 and held it in 19 quarters. The position peaked at $2.07M in Q4 2021. 3,076 funds tracked by Wall St. Rank hold ABBV as of Q2 2023.

  • Kalos Management reported no remaining AbbVie position as of Q2 2023 after selling out during the quarter.
  • Kalos Management sold 165 AbbVie shares in Q2 2023, an estimated $26.3K.
  • Kalos Management first reported a position in AbbVie in Q4 2015 and held it in 19 quarters.
  • Kalos Management's AbbVie position peaked at $2.07M in Q4 2021.
  • 3,076 funds tracked by Wall St. Rank held AbbVie as of Q2 2023.

Based on Kalos Management's 13F filing for Q2 2023, filed 9 Aug 2023.